Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq
Location
Seattle, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 217 % +6.24%
Debt-to-equity 145 % -13.2%
Return On Equity -389 % -11.6%
Return On Assets -159 % -21.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares -8.98%
Common Stock, Shares, Outstanding 13.8M shares -19%
Entity Public Float 1.2M USD -89.1%
Common Stock, Value, Issued 110K USD +34.1%
Weighted Average Number of Shares Outstanding, Basic 4.05M shares +28306%
Weighted Average Number of Shares Outstanding, Diluted 4.05M shares +28306%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.9M USD +5.66%
General and Administrative Expense 11.8M USD +12.3%
Operating Income (Loss) -26.7M USD -8.52%
Net Income (Loss) Attributable to Parent -26.5M USD -11.6%
Earnings Per Share, Basic 1.86K USD/shares +99.4%
Earnings Per Share, Diluted 1.86K USD/shares +99.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.1M USD +172%
Other Assets, Current 77K USD -87.7%
Assets, Current 22.6M USD +126%
Property, Plant and Equipment, Net 384K USD -37.5%
Operating Lease, Right-of-Use Asset 3.96M USD -12.3%
Assets 27M USD +78.2%
Employee-related Liabilities, Current 1.9M USD +106%
Liabilities, Current 5.61M USD -4.56%
Operating Lease, Liability, Noncurrent 3.99M USD -16.9%
Other Liabilities, Noncurrent 0 USD
Liabilities 9.6M USD -10.5%
Retained Earnings (Accumulated Deficit) -269M USD -11.6%
Stockholders' Equity Attributable to Parent 17.4M USD +293%
Liabilities and Equity 27M USD +78.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.58M USD +1.14%
Net Cash Provided by (Used in) Financing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 13.8M shares -19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.58M USD +1.19%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD -30.1%
Deferred Tax Assets, Valuation Allowance 49.2M USD -7.59%
Deferred Tax Assets, Gross 50.1M USD -7.64%
Operating Lease, Liability 5.4M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 7.34M USD -15.8%
Property, Plant and Equipment, Gross 14.5M USD 0%
Operating Lease, Liability, Current 800K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.94M USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.38M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 344K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 61K USD -42.5%
Deferred Tax Assets, Net of Valuation Allowance 922K USD -10.2%
Share-based Payment Arrangement, Expense 530K USD -73.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%